(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual revenue growth rate of 212.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Werewolf Therapeutics's revenue in 2025 is $1,143,000.On average, 1 Wall Street analysts forecast HOWL's revenue for 2025 to be $269,241,876, with the lowest HOWL revenue forecast at $269,241,876, and the highest HOWL revenue forecast at $269,241,876. On average, 1 Wall Street analysts forecast HOWL's revenue for 2026 to be $2,243,682,300, with the lowest HOWL revenue forecast at $2,243,682,300, and the highest HOWL revenue forecast at $2,243,682,300.
In 2027, HOWL is forecast to generate $1,041,068,587 in revenue, with the lowest revenue forecast at $1,041,068,587 and the highest revenue forecast at $1,041,068,587.